A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Key facts
- Where
- Kilifi, Machakos, Nairobi, and Thika, KenyaSee the 5 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 90 years old?
Source: NCT05878769, who can take part
Where in Kenya
- KEMRI-MTWAPA Clinical Trial SiteKilifi, KenyaTaking people
- Clinical Research Health Network (CREA-N)Machakos, KenyaTaking people
- KEMRI CRDR Clinical Research Clinic NairobiNairobi, KenyaTaking people
- University of Nairobi Clinical Research CentreNairobi, KenyaTaking people
- Center for Research In Tropical Medicine and community developmentThika, KenyaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Hoffmann-La Roche
- Trial code
- NCT05878769
- Record updated
- 12 November 2026
- Original description
The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment period in parent studies GB43311 or GB44332.Read full original descriptionShow less
A Phase III Open-Label Extension Study to Evaluate the Long-Term Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease
The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment period in parent studies GB43311 or GB44332.
Inclusion: Completion of the 52-week treatment period in an astegolimab parent study.
Exclusion: Any permanent discontinuation of study drug in parent study; Any new clinically significant pulmonary disease other than COPD (e.g., pulmonary fibrosis, sarcoidosis, chronic pulmonary embolism or primary pulmonary hypertension, alpha-1-antitrypsin deficiency) since enrolling in the parent study; Any new unstable cardiac disease, myocardial infarction, or New York Heart Association Class III or IV heart failure since enrolling in the parent study; Withdrawal of consent and/or premature discontinuation from parent study; Significant non-compliance in the parent study, specifically defined as missing scheduled visits, per investigator's judgment; Any new diagnosis of asthma according to the Global Initiative for Asthma guidelines or other accepted guidelines since enrolling in the parent study.